172 related articles for article (PubMed ID: 35793867)
21. POLE/POLD1 mutation and tumor immunotherapy.
Ma X; Dong L; Liu X; Ou K; Yang L
J Exp Clin Cancer Res; 2022 Jul; 41(1):216. PubMed ID: 35780178
[TBL] [Abstract][Full Text] [Related]
22. Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors.
Lee M; Eng G; Barbari SR; Deshpande V; Shcherbakova PV; Gala MK
Clin Transl Gastroenterol; 2020 Mar; 11(3):e00149. PubMed ID: 32352724
[TBL] [Abstract][Full Text] [Related]
23. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ
Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091
[TBL] [Abstract][Full Text] [Related]
24. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a
Gong J; Wang C; Lee PP; Chu P; Fakih M
J Natl Compr Canc Netw; 2017 Feb; 15(2):142-147. PubMed ID: 28188185
[TBL] [Abstract][Full Text] [Related]
25. High prevalence of unusual KRAS, NRAS, and BRAF mutations in POLE-hypermutated colorectal cancers.
Favre L; Cohen J; Calderaro J; Pécriaux A; Nguyen CT; Bourgoin R; Larnaudie L; Dupuy A; Ollier M; Lechapt E; Sloma I; Tournigand C; Rousseau B; Pujals A
Mol Oncol; 2022 Sep; 16(17):3055-3065. PubMed ID: 35624529
[TBL] [Abstract][Full Text] [Related]
26. DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity.
Castellucci E; He T; Goldstein DY; Halmos B; Chuy J
Oncologist; 2017 May; 22(5):497-502. PubMed ID: 28465371
[TBL] [Abstract][Full Text] [Related]
27. Exploring the basis of heterogeneity of cancer aggressiveness among the mutated POLE variants.
Selves J; de Castro E Gloria H; Brunac AC; Saffi J; Guimbaud R; Brousset P; Hoffmann JS
Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37891003
[TBL] [Abstract][Full Text] [Related]
28. Non-Exonuclease Domain POLE Mutations Associated with Immunotherapy Benefit.
Dong S; Zakaria H; Hsiehchen D
Oncologist; 2022 Mar; 27(3):159-162. PubMed ID: 35274726
[TBL] [Abstract][Full Text] [Related]
29. Ultra-mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns.
Hu H; Cai W; Wu D; Hu W; Dong Wang L; Mao J; Zheng S; Ge W
Cancer Med; 2021 Jan; 10(1):135-142. PubMed ID: 33125191
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological and mutational analyses of colorectal cancer with mutations in the POLE gene.
Hino H; Shiomi A; Kusuhara M; Kagawa H; Yamakawa Y; Hatakeyama K; Kawabata T; Oishi T; Urakami K; Nagashima T; Kinugasa Y; Yamaguchi K
Cancer Med; 2019 Aug; 8(10):4587-4597. PubMed ID: 31240875
[TBL] [Abstract][Full Text] [Related]
31. Distinct clinical pattern of colorectal cancer patients with POLE mutations: A retrospective study on real-world data.
Jiang M; Jia Y; Han J; Shi J; Su C; Zhang R; Xing M; Jin S; Zong H
Front Genet; 2022; 13():963964. PubMed ID: 36479248
[No Abstract] [Full Text] [Related]
32. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
33. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
Domingo E; Freeman-Mills L; Rayner E; Glaire M; Briggs S; Vermeulen L; Fessler E; Medema JP; Boot A; Morreau H; van Wezel T; Liefers GJ; Lothe RA; Danielsen SA; Sveen A; Nesbakken A; Zlobec I; Lugli A; Koelzer VH; Berger MD; Castellví-Bel S; Muñoz J; ; de Bruyn M; Nijman HW; Novelli M; Lawson K; Oukrif D; Frangou E; Dutton P; Tejpar S; Delorenzi M; Kerr R; Kerr D; Tomlinson I; Church DN
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):207-216. PubMed ID: 28404093
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
Song Z; Cheng G; Xu C; Wang W; Shao Y; Zhang Y
Lung Cancer; 2018 Apr; 118():57-61. PubMed ID: 29572003
[TBL] [Abstract][Full Text] [Related]
35. PD-1 Blockade Elicits Ongoing Remission in Two Cases of Refractory Microsatellite-Stable Cancer Harboring a POLE Mutation.
Schenck K; Masetti M; Pfarr N; Lorenzen S
Oncol Res Treat; 2022; 45(4):222-226. PubMed ID: 34875656
[TBL] [Abstract][Full Text] [Related]
36. Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε (POLE).
Forgó E; Gomez AJ; Steiner D; Zehnder J; Longacre TA
Histopathology; 2020 Feb; 76(3):366-374. PubMed ID: 31479159
[TBL] [Abstract][Full Text] [Related]
37. Distinctive genomic characteristics in
He J; Ouyang W; Zhao W; Shao L; Li B; Liu B; Wang D; Han-Zhang H; Zhang Z; Shao L; Li W
Ann Transl Med; 2021 Jan; 9(2):129. PubMed ID: 33569431
[TBL] [Abstract][Full Text] [Related]
38. Endometrial Carcinomas with a "Serous" Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations.
Conlon N; Da Cruz Paula A; Ashley CW; Segura S; De Brot L; da Silva EM; Soslow RA; Weigelt B; DeLair DF
Am J Surg Pathol; 2020 May; 44(5):641-648. PubMed ID: 32205482
[TBL] [Abstract][Full Text] [Related]
39. POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy.
Chen YX; Wang ZX; Yuan SQ; Jiang TJ; Huang YS; Xu RH; Wang F; Zhao Q
Clin Transl Med; 2021 Sep; 11(9):e524. PubMed ID: 34586735
[No Abstract] [Full Text] [Related]
40. TTN/OBSCN 'Double-Hit' predicts favourable prognosis, 'immune-hot' subtype and potentially better immunotherapeutic efficacy in colorectal cancer.
Liu Z; Wang L; Guo C; Liu L; Jiao D; Sun Z; Wu K; Zhao Y; Han X
J Cell Mol Med; 2021 Apr; 25(7):3239-3251. PubMed ID: 33624434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]